ReGen Biologics (OTC: RGBO) (“ReGen” or “the company”) is pleased to report that Steven Tradonsky, MD of San Diego Sports Medicine recently treated a young veteran with the Menaflex collagen meniscus implant at the VA Medical Center in La Jolla, California.
Dr. Tradonsky noted, “The patient previously had a partial meniscectomy and was returning for an ACL reconstruction. Based on his ongoing symptoms, it was a wonderful opportunity to offer a new option that previously was not available prior to the Menaflex clearance.”
“We're delighted to provide veterans and active armed forces a new alternative to the permanent loss of tissue associated with partial meniscectomy,” noted Jeff Chandler, ReGen’s Senior VP of Sales and Marketing. “Partial meniscectomy is the highest volume surgical orthopedic knee procedure, and now surgeons have the option to put something back when tissue is removed from patients with either chronic or acute injuries.”
Many of the over 120 surgeons trained in the use of the Menaflex implant are now actively seeking patients and incorporating the new device into their protocol for treating patients with similar chronic meniscal injuries. A list of trained surgeons can be accessed at www.menaflex.com.
Patient-derived organoids: Transforming cancer research and personalized medicine